Accéder au contenu
MilliporeSigma
Toutes les photos(3)

Key Documents

17-648

Sigma-Aldrich

ChIPAb+ Dimethyl-Histone H3 (Lys9) - ChIP Validated Antibody and Primer Set

serum, from rabbit

Synonyme(s) :

H3K9me2, Histone H3 (di methyl K9), Histone H3K9me2

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme


About This Item

Code UNSPSC :
12352203
eCl@ss :
32160702
Nomenclature NACRES :
NA.52

Source biologique

rabbit

Niveau de qualité

Forme d'anticorps

serum

Clone

polyclonal

Espèces réactives

human, mouse

Réactivité de l'espèce (prédite par homologie)

mammals

Fabricant/nom de marque

ChIPAb+
Upstate®

Technique(s)

ChIP: suitable
immunoprecipitation (IP): suitable
western blot: suitable

Numéro d'accès NCBI

Numéro d'accès UniProt

Conditions d'expédition

dry ice

Informations sur le gène

human ... H3F3B(3021)

Description générale

All ChIPAb+ antibodies are individually validated for chromatin precipitation, every lot, every time. Each ChIPAb+ antibody set includes control primers (tested every lot by qPCR) to biologically validate your IP results in a locus-specific context. The qPCR protocol and primer sequences are provided, allowing researchers to validate ChIP protocols when using our antibody in their chromatin context. Each set also includes a negative control antibody to ensure specificity of the ChIP reaction.
The ChIPAb+ Dimethyl-Histone H3 (Lys9) set includes the anti-dimethyl-histone H3 (Lys9) antibody, a negative control antibody (normal rabbit serum), and qPCR primers which amplify a 110 bp region within the promoter of the human β-globin gene. The dimethyl-histone H3 (Lys9) and negative control antibodies are supplied in a scalable "per ChIP" reaction size and can be used to functionally validate the precipitation of dimethyl-histone H3 (Lys9) associated chromatin.
The methylation of histones can occur on two different residues: arginine or lysine. Histone methylation can be associated with transcriptional activation or repression, depending on the methylated residue. Lysine 9 of histone H3 can be mono-, di- or trimethylated by different histone methyltransferases (HMTs) such as SuvH39H1 or G9a. This methylated lysine can be demethylated by histone demethylases as JMJD1A, LSD1 or JMJD2C. Methylation of this residue is mainly associated with transcriptional repression.

Spécificité

Dimethyl-Histone H3 (Lys9)

Immunogène

Epitope: Dimethyl Lys9
The dimethyl-histone H3 (Lys9) rabbit serum is made against a KLH-conjugated, branched synthetic peptide containing the sequence ..Rme2KSTG.., in which me2K corresponds to dimethyl-lysine at residue 9 of human histone H3

Application

Chromatin Immunoprecipitation:
Sonicated chromatin prepared from untreated HeLa cells (1 X 106 cell equivalents) was subjected to chromatin Immunoprecipitation using 4 μL of either a normal rabbit antiserum or Antidimethyl-Histone H3 (Lys9) serum and the Magna ChIP A (Cat. #17-610) Kit (Please see figures). Successful Immunoprecipitation of dimethyl-histone H3 (Lys9) associated DNA fragments was verified by qPCR using β-globin ChIP Primers flanking the human β-globin promoter or primers amplifying the promoter of human GAPDH, which is transcriptionally inactive in HeLa cells. Percent Input relative to standard curves for each qPCR primer set are shown.
Please refer to the EZ-Magna A ChIP (Cat. # 17-408) or EZ-ChIP (Cat. # 17-371) protocol for experimental details.

Western blot analysis and peptide inhibition:
HeLa Acid extract were resolved by electrophoresis, transferred to nitrocellulose and probed with anti-dimethyl-Histone H3 (Lys9) (1:500, Lane 1) or preincubated with 0.4 μM Histone H3 peptide with following modifications:
Lane 2: Linear non-modified
Lane 3: Branched non-modified
Lane 4: Branched trimethyl
Lane 5: Linear trimethyl
Lane 6: Branched dimethyl
Lane 7: Linear dimethyl
Lane 8: Branched monomethyl
Lane 9: Linear monomethyl
Proteins were visualized using a goat anti–rabbit secondary antibody conjugated to HRP and a chemiluminescence detection system.
Dimethyl-Histone H3 (Lys9) ChIP validated antibody & primer set including the ChIP-grade antibody & the specific control PCR primers used for chromatin immunoprecipitation of H3K9Me2.
Research Category
Epigenetics & Nuclear Function
Research Sub Category
Chromatin Biology

Conditionnement

25 assays per kit, ~4μL per chromatin immunoprecipitation

Composants

Anti-Dimethyl-Histone H3 (Lys9) (rabbit serum), 1 vial

Negative ChIP Control serum, 1 vial

ChIP Primers β-globin , 1 vial

Qualité

Chromatin Immunoprecipitation:
Sonicated chromatin prepared from untreated HeLa cells (1 X 106 cell equivalents) was subjected to chromatin immunoprecipitation using 4 μL of either a normal rabbit antiserum or 4 μL Anti-Dimethyl-Histone H3 (Lys9) serum and the Magna ChIP A (Cat. #17-610) Kit.
Successful immunoprecipitation of dimethyl histone H3 (Lys9) associated DNA fragments was verified by qPCR using control ChIP Primers flanking the β-globin human promoter (Please see figures).

Description de la cible

17 kDa

Forme physique

Dimethyl-Histone H3 (Lys9) (rabbit polyclonal serum). One vial containing 100 μL of antiserum containing 0.05% sodium azide.

Normal Rabbit Serum. One vial containing 100 uL antiserum containing 0.05% sodium azide.

ChIP Primers, β-Globin. One vial containing 75 μL of 5 μM of each primer specific for human β-globin.
FOR: AGG ACA GGT ACG GCT GTC ATC
REV: TTT ATG CCC AGC CCT GGC TC

Stockage et stabilité

Stable for 1 year at -20°C from date of receipt

Remarque sur l'analyse

Control
Included negative control antibody normal rabbit serum and control primers specific for human β-globin promoter.

Informations légales

UPSTATE is a registered trademark of Merck KGaA, Darmstadt, Germany

Clause de non-responsabilité

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

Code de la classe de stockage

10 - Combustible liquids


Certificats d'analyse (COA)

Recherchez un Certificats d'analyse (COA) en saisissant le numéro de lot du produit. Les numéros de lot figurent sur l'étiquette du produit après les mots "Lot" ou "Batch".

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Haobin Chen et al.
Carcinogenesis, 31(12), 2136-2144 (2010-10-01)
Epigenetic silencing of tumor suppressor genes commonly occurs in human cancers via increasing DNA methylation and repressive histone modifications at gene promoters. However, little is known about how pathogenic environmental factors contribute to cancer development by affecting epigenetic regulatory mechanisms.
Youhua Tan et al.
Nature communications, 5, 4619-4619 (2014-08-08)
Tumour-repopulating cells (TRCs) are a self-renewing, tumorigenic subpopulation of cancer cells critical in cancer progression. However, the underlying mechanisms of how TRCs maintain their self-renewing capability remain elusive. Here we show that relatively undifferentiated melanoma TRCs exhibit plasticity in Cdc42-mediated
Youhua Tan et al.
Biochemical and biophysical research communications, 483(1), 456-462 (2016-12-23)
Tumor-repopulating cells (TRCs) are a tumorigenic sub-population of cancer cells that drives tumorigenesis. We have recently reported that soft fibrin matrices maintain TRC growth by promoting histone 3 lysine 9 (H3K9) demethylation and Sox2 expression and that Cdc42 expression influences
Yuxia Zhang et al.
FEBS letters, 585(9), 1269-1275 (2011-04-05)
We describe a transcriptional mechanism regulating the expression of Dnmt1 by nuclear receptors. We show that ERRγ functions as a transcriptional activator of mouse and human Dnmt1 expression by direct binding to its response elements (ERE1/ERE2) in the dnmt1/DNMT1 promoters.
Marianna Rodova et al.
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 26(8), 1974-1986 (2011-04-01)
The development of disease-modifying pharmacologic therapy for osteoarthritis (OA) currently faces major obstacles largely because the regulatory mechanisms for the function of adult articular chondrocytes remain unclear. We previously demonstrated that lack of Nfat1, one of the nuclear factor of

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique